While this still supports that 177Lu-lilotomab satetraxetan successfully targets the viable tumor cells in the volume of interest determined from baseline FDG PET, it also indicates that FDG uptake intensity does not necessarily correlates with CD37 expression in tumor. This evidence concerns the gene CD37 and neoplasm.